Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant lapatinib versus trastuzumab with EC followed by paclitaxel in HER2-positive breast cancer
2010-018389-22Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib, trastuzumab, epirubicin, cyclophosphamide and paclitaxel in breast cancer (2 arms), sponsored by GSK. Primary endpoint: Pathologic complete response in the breast. Started Aug 2010; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-018389-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018389-22.